tirzepatide vs semaglutide potency & are transforming diabetes & obesity management. These GLP-1 receptor agonists offer benefits from glycemic control to weight loss and cardiovascular risk reduction, emphasizing their broad impact. Read more from Comparative safety and side effects

In short, a slight average rise in resting heart rate has appeared alongside overall reductions in major cardiac events in clinical studies

New GLP-1 agonists beat Ozempic and Wegovy in studies And of course, generics development aside, biopharmas are creating more GLP-1 agonists that could outperform Ozempic and Wegovy

Compare formats with BPC-Lx Pro Spray

As more patients are asking us about peptide therapy, it's important to have a conversation to determine the clinical need for these and other medications to determine the medical appropriateness

Retatrutide is a once-weekly injection being developed by Eli Lilly to treat obesity